INTRODUCING THE TARGETED ANTICANCER THERAPIES AND PRECISION MEDICINE IN CANCER COLLECTION

  • MPNRF | April 6, 2021

    Since the discovery of driver mutations JAK2, CALR and MPPL in myeloproliferative neoplasms, the patient and caregivers effected have dreamed about a therapy that would target this mutation and stop the disease in its tracks. There have been no such epiphanies to date, but we hold out hope. This article on the evolution of cancer therapies discusses advancement in a JAK2 mouse model, which is one of the steps on the way to creating therapies and eventually a cure for humans.”

    CLICK HERE TO READ THE FULL ARTICLE